Considering the above results, we have taken CYP1A1, CYP2B6, CYP3A4, UGT1A8, UGT2B11, UGT2B17, UGT2B7, GAS5, XIST, SNHG6, which might be more relevant to chemotherapy or endocrine therapy resistance in PCa treatment, for subsequent study. The gene discussed is CYP2B6; the disease is posterior cortical atrophy.